Immunogenic properties of the Plasmodium vivax vaccine candidate MSP119 expressed as a secreted non-glycosylated polypeptide from Pichia pastoris

Parasitology

Volumn 124, Issue 3, 2002, Pages 237-246

  Soares, I S ^a   Rodrigues, M M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Malaria; MSP1; Plasmodium vivax; Recombinant protein

Indexed keywords

EPITOPE; FREUND ADJUVANT; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; PAN ALLELIC DR EPITOPE; PROTOZOON ANTIBODY; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG ANTIGENICITY; DRUG FORMULATION; EPITOPE MAPPING; FEMALE; IMMUNOGENICITY; MALARIA; MOUSE; NONHUMAN; PICHIA PASTORIS; PLASMODIUM VIVAX; PRIORITY JOURNAL; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, PROTOZOAN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNITY, CELLULAR; IMMUNIZATION; MALARIA VACCINES; MALARIA, VIVAX; MEROZOITE SURFACE PROTEIN 1; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PICHIA; PLASMODIUM VIVAX; VACCINES, SYNTHETIC;

ANIMALIA; PICHIA; PICHIA PASTORIS; PLASMODIUM VIVAX; PRIMATES; PROTOZOA;

EID: 0036196194     PISSN: 00311820     EISSN: None     Source Type: Journal    
DOI: 10.1017/S003118200100110X     Document Type: Article

References (31)

1. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides
2. Plasmodium falciparum: Merozoite Surface Protein 1 and 2 are not posttranslationally modified by classical N- or O-glycans
3. Glycosylation of Pichia pastoris-derived proteins
4. Immunization of Aotus nancymai with recombinant C terminus of Plasmodium falciparum merozoite surface protein 1 in liposomes and alum adjuvant does not induce protection against a challenge infection
5. Both epidermal growth factor-like domains of the merozoite surface protein-1 from Plasmodium yoelii are required for protection from malaria
6. Heterologous protein expression in the methylotrophic yeast Pichia pastoris
7. The crystal structure of C-terminal merozoite surface protein 1 at 18 Å resolution, a highly protective malaria vaccine candidate
8. 19 expressed in distinct bacterial vectors
9. A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii 17XL merozoite surface protein-1 induces a protective immune response in mice
10. A rational approach to improving productivity in recombinant Pichia pastoris fermentation
11. Antigenic properties of the merozoite surface protein 1 gene of Plasmodium vivax
12. Pathways and strategies for developing a malaria blood-stage vaccine
13. Characterization of C-terminal merozoite surface protein-1 baculovirus recombinant proteins from Plasmodium vivax and Plasmodium cynomolgi as recognized by the natural anti-parasite immune response
14. Protection of Aotus monkeys by Plasmodium falciparum EBA-175 Region II DNA prime-protein boost immunization regimen
15. Immune effects and mechanisms of action of CpG motifs
16. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys
17. Immunogenicity and efficacy in Aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1
18. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell response to protein antigen: A new class of vaccine adjuvant
19. Immunization against malaria with a recombinant protein
20. The combine epidermal growth factor-like modules of Plasmodium yoelii Merozoite Surface Protein-1 are required for a protective immune response to the parasite
21. CpG DNA is a potent enhancer of systemic and mucosal immune response against hepatitis B surface antigen with intranasal administration to mice
22. Dimorphism of the C terminus of the Plasmodium vivax merozoite surface protein 1
23. Naturally acquired antibody responses to the C-terminal region of merozoite surface protein 1 of Plasmodium vivax in Korea
24. Baculovirus merozoite surface protein 1 C-terminal recombinant antigens are highly protective in a natural primate model for human Plasmodium vivax malaria
25. Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene
26. Advances in vaccine adjuvances
27. Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria
28. A Plasmodium vivax vaccine candidate displays limited allele polymorphism, which does not restrict recognition bv antibodies
29. Longevity of the naturally acquired antibody responses to the N- and C-terminal regions of Plasmodium vivax MSP1
30. Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant
31. Biochemical and immunological properties of a viral hybrid particle expressing the Plasmodium vivax merozoite surface protein 1 C-terminal region